Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | GCGR | P47871 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4919053 | 0.87 | HSD17B3 (0.40) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ROCK2 | |
| SCHEMBL4911086 | 0.81 | HSD17B3 (0.41) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ROCK2 | |
| SCHEMBL4914858 | 0.79 | HSD17B3 (0.39) | HPGDSMN1; SMN2L3MBTL1ALDH1A1ROCK2 | |
| SCHEMBL27988532 | 0.72 | AKT1 (0.44) | L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3636594 | 0.72 | CYP1A2 (0.55) | SMN1; SMN2L3MBTL1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3636468 | 0.71 | NAMPT (0.51) | HPGDSMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL4914541 | 0.71 | HPGD (0.42) | HPGDSMN1; SMN2L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL4916551 | 0.71 | F2 (0.41) | HPGDSMN1; SMN2L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL4915274 | 0.71 | HPGD (0.40) | HPGDSMN1; SMN2L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL4912835 | 0.70 | HSD17B3 (0.39) | HPGDSMN1; SMN2L3MBTL1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | claimed |
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | HPGD 994/4885SMN1; SMN2 1228/4885L3MBTL1 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.